JP2022510736A5 - - Google Patents

Info

Publication number
JP2022510736A5
JP2022510736A5 JP2021554804A JP2021554804A JP2022510736A5 JP 2022510736 A5 JP2022510736 A5 JP 2022510736A5 JP 2021554804 A JP2021554804 A JP 2021554804A JP 2021554804 A JP2021554804 A JP 2021554804A JP 2022510736 A5 JP2022510736 A5 JP 2022510736A5
Authority
JP
Japan
Prior art keywords
group
ring
substituted
atom
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021554804A
Other languages
English (en)
Japanese (ja)
Other versions
JP7895177B2 (ja
JP2022510736A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/048593 external-priority patent/WO2020116660A1/en
Publication of JP2022510736A publication Critical patent/JP2022510736A/ja
Publication of JP2022510736A5 publication Critical patent/JP2022510736A5/ja
Priority to JP2024102161A priority Critical patent/JP2024123202A/ja
Application granted granted Critical
Publication of JP7895177B2 publication Critical patent/JP7895177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021554804A 2018-12-05 2019-12-04 大環状化合物とその使用 Active JP7895177B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024102161A JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024102161A Division JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Publications (3)

Publication Number Publication Date
JP2022510736A JP2022510736A (ja) 2022-01-27
JP2022510736A5 true JP2022510736A5 (cg-RX-API-DMAC7.html) 2022-11-30
JP7895177B2 JP7895177B2 (ja) 2026-07-27

Family

ID=70975488

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021554804A Active JP7895177B2 (ja) 2018-12-05 2019-12-04 大環状化合物とその使用
JP2024102161A Pending JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024102161A Pending JP2024123202A (ja) 2018-12-05 2024-06-25 大環状化合物とその使用

Country Status (18)

Country Link
US (1) US11518763B2 (cg-RX-API-DMAC7.html)
EP (1) EP3890738A4 (cg-RX-API-DMAC7.html)
JP (2) JP7895177B2 (cg-RX-API-DMAC7.html)
KR (1) KR102919982B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164468A (cg-RX-API-DMAC7.html)
AR (1) AR117251A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391942B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010704A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121952C (cg-RX-API-DMAC7.html)
CL (1) CL2021001451A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007304A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006527A (cg-RX-API-DMAC7.html)
NZ (1) NZ776102A (cg-RX-API-DMAC7.html)
PH (1) PH12021551262A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105125XA (cg-RX-API-DMAC7.html)
TW (1) TWI820266B (cg-RX-API-DMAC7.html)
UA (1) UA127872C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020116660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
BR112023004567A2 (pt) * 2020-09-14 2023-04-04 Sanofi Sa Derivados de tetrahidroisoquinolina para o tratamento de doenças do sangue e doenças inflamatórias
AU2024251986A1 (en) * 2023-04-03 2025-10-16 Acelink Therapeutics, Inc. Novel compounds and uses thereof
CN119707895B (zh) * 2023-12-18 2026-03-31 江苏苏中药业研究院有限公司 一种7-甲酰基-2,3-二氢苯并呋喃-4-碳腈的制备方法
WO2026026967A1 (zh) * 2024-08-02 2026-02-05 劲方医药科技(上海)股份有限公司 丙烯酰基类化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103270022B (zh) 2010-08-31 2015-08-19 巴勃罗·比咯斯拉达 神经营养蛋白受体激动剂及其作为药物的应用
KR102322794B1 (ko) 2013-06-21 2021-11-05 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
ES2784244T3 (es) 2013-12-18 2020-09-23 Glaxosmithkline Ip Dev Ltd Reguladores de Nrf2
LT3307739T (lt) 2015-06-15 2021-03-10 Glaxosmithkline Intellectual Property Development Limited Nrf2 reguliatoriai
KR20180017038A (ko) 2015-06-15 2018-02-20 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
AU2016280236B2 (en) 2015-06-15 2019-02-07 Astex Therapeutics Limited Nrf2 regulators
WO2017026516A1 (ja) 2015-08-12 2017-02-16 持田製薬株式会社 イソチアゾール誘導体
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
US10351530B2 (en) 2015-10-06 2019-07-16 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as NRF2 regulators
WO2018109641A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited 3-carboxylic acid pyrroles as nrf2 regulators
WO2018109642A1 (en) 2016-12-12 2018-06-21 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
ES2901617T3 (es) 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
EP3555068B1 (en) 2016-12-14 2020-12-02 GlaxoSmithKline Intellectual Property Development Limited 3-oxo-1,4-diazepinyle compounds as nrf2 activators
JP2020502123A (ja) 2016-12-14 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのビスアリール複素環
JP2020502152A (ja) 2016-12-15 2020-01-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2アクチベーターとしてのエーテル結合トリアゾール
AU2017376900A1 (en) 2016-12-15 2019-05-23 Glaxosmithkline Intellectual Property Development Limited NRF2 compounds
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
EP3573963B1 (en) 2017-01-30 2021-09-01 Biogen MA Inc. Nrf2 activator
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Similar Documents

Publication Publication Date Title
JP2022512482A5 (cg-RX-API-DMAC7.html)
JP2024518554A5 (cg-RX-API-DMAC7.html)
JP2021011503A5 (ja) 製剤用脂質ナノ粒子
JP2012522759A5 (cg-RX-API-DMAC7.html)
RU2005123802A (ru) Производные адамантана, способы их получения и содержащие их фармацевтические композиции
JP2012532883A5 (cg-RX-API-DMAC7.html)
JP2008503515A5 (cg-RX-API-DMAC7.html)
JP2016506916A5 (cg-RX-API-DMAC7.html)
JP2015537020A5 (cg-RX-API-DMAC7.html)
JP2018534348A5 (cg-RX-API-DMAC7.html)
JP2014511840A5 (cg-RX-API-DMAC7.html)
CA2506082A1 (en) Novel medicaments for the treatment of chronic obstructive pulmonary disease
RU2013140169A (ru) Противоопухолевое терапевтическое средство
JP2011504903A5 (cg-RX-API-DMAC7.html)
JP2013542992A5 (cg-RX-API-DMAC7.html)
JP2017141277A5 (cg-RX-API-DMAC7.html)
EP4606812A3 (en) 9(11)-unsaturated neuroactive steroids and their methods of use
JP2020063289A5 (cg-RX-API-DMAC7.html)
JP2014505017A5 (cg-RX-API-DMAC7.html)
PH12017501428A1 (en) 4-substituted benzoxaborole compounds and uses thereof
JP2018521056A5 (cg-RX-API-DMAC7.html)
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
JP2004523478A5 (cg-RX-API-DMAC7.html)
JP2020517738A5 (cg-RX-API-DMAC7.html)